Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: Revised and updated results

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 626-629

  Hayes, D F ^a   Skaar, T C ^b   Rae, J M ^a   Henry, N L ^a   Nguyen, A T ^b   Stearns, V ^c   Li, L ^b   Philips, S ^b   Desta, Z ^b   Flockhart, D A ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b INDIANA UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL; CHOLESTEROL; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR ALPHA, HUMAN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; MENOPAUSE; PHARMACOGENETICS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; GENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TIME; TREATMENT OUTCOME;

BREAST NEOPLASMS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOCHROME P-450 CYP2D6; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENOTYPE; HUMANS; LIPIDS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PREMENOPAUSE; REPRODUCIBILITY OF RESULTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77958474560     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.143     Document Type: Article

References (7)

1. MacGregor, J.I. & Jordan, V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50, 151-196 (1998).
2. Ntukidem, N.I. et al.; Consortium on Breast Cancer Pharmacogenomics. Estrogen receptor genotypes, menopausal status, and the lipid efects of tamoxifen. Clin. Pharmacol. Ther. 83, 702-710 (2008).
3. Massart, F. Human races and pharmacogenomics of efective bone treatments. Gynecol. Endocrinol. 20, 36-44 (2005).
4. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003).
5. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
6. Herrington, D.M. et al. Estrogen-receptor polymorphisms and efects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N. Engl. J. Med. 346, 967-974 (2002).
7. Onitilo, A.A. et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res. Treat. 115, 643-650 (2009).